Literature DB >> 12552988

Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study.

C Christodolou1, N Pavlidis, E Samantas, G Fountzilas, G Kouvatseas, K Pagdatoglou, F Palamidas, C Nikolaidis, M Angelidou, H P Kalofonos, P Kosmidis, D V Skarlos.   

Abstract

BACKGROUND: Prognostic factors among Greek patients with SCLC were evaluated. PATIENTS AND METHODS: Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis was performed.
RESULTS: Complete response (CR) was achieved in 26.8% and partial response in 40.1% of patients. The median duration of response was 7.4 months, the median survival 10.5 months and the 2-year survival rate 12%. The stage of the disease was a dominant prognostic factor for survival and response. PS 0-1 was a major prognostic factor for survival, duration of response and CR. Female gender was a favorable predictor for CR. Superior vena cava syndrome was a poor prognostic factor for survival and duration of response. Weight loss and age > or = 60 were poor predictors for response. The sites of metastases affected survival, duration of response and response. Normal alkaline phosphatase was a favorable prognostic factor for survival, duration of response and response. Normal lactate dehydrogenase and thoracic irradiation were favorable prognostic factors for survival and duration of response.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12552988

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Radiation dose is associated with prognosis of small cell lung cancer with superior vena cava syndrome.

Authors:  Zhen-Bo Wang; Fang-Ling Ning; Xiao-Le Wang; Yu-Feng Cheng; Xin-Jun Dong; Chang-Min Liu; Shao-Shui Chen
Journal:  Int J Clin Exp Med       Date:  2015-03-15

2.  Prognostic factors in patients with small cell lung carcinoma.

Authors:  S Arinc; U Gonlugur; O Devran; N Erdal; F Ece; M Ertugrul; D Derince; O Oruc; A Hazar
Journal:  Med Oncol       Date:  2009-04-28       Impact factor: 3.064

3.  Development and validation of a nomogram for assessing survival in extensive-stage small-cell lung cancer patients with superior vena cava syndrome referred for thoracic radiotherapy: a comparison of upfront vs. consolidative approaches.

Authors:  Ting Mei; Weigang Xiu; Xuexi Yang; Xiaoman Tian; Yang Yu; Yong Xu; Lin Zhou; Xiaojuan Zhou; Yongmei Liu; Bingwen Zou; Jianxin Xue; Rui Ao; You Lu; Youling Gong
Journal:  Strahlenther Onkol       Date:  2021-04-28       Impact factor: 3.621

4.  Clinical significance of the cachexia index in patients with small cell lung cancer.

Authors:  Se-Il Go; Mi Jung Park; Gyeong-Won Lee
Journal:  BMC Cancer       Date:  2021-05-17       Impact factor: 4.430

5.  Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer.

Authors:  Seigo Minami; Yoshitaka Ogata; Shouichi Ihara; Suguru Yamamoto; Kiyoshi Komuta
Journal:  Lung Cancer (Auckl)       Date:  2016-04-05

6.  Paclitaxel for treatment of advanced small cell lung cancer (SCLC): a retrospective study of 185 patients.

Authors:  Damian von Eiff; Farastuk Bozorgmehr; Inn Chung; Denise Bernhardt; Stefan Rieken; Stephan Liersch; Thomas Muley; Sonja Kobinger; Michael Thomas; Petros Christopoulos; Martin Steins
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 2.895

7.  Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?

Authors:  P J Ross; S Ashley; A Norton; K Priest; J S Waters; T Eisen; I E Smith; M E R O'Brien
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.